Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Mammalian myeloid progenitor cell subsets |
| Inventors: | Weissman, Irving L.; Redwood City, CA, USA Traver, David Jeffrey; West Roxbury, MA, USA Akashi, Koichi; Palo Alto, CA, USA Manz, Markus Gabriel; Palo Alto, CA, USA Miyamoto, Toshihiro; Menlo Park, CA, USA |
| Summary: | Described herein is a mammalian myeloid progenitor cell composition, and its uses as a source of lineage and cell specific products. The invention relates to a substantially enriched mammalian hematopoietic cell subpopulation which is characterized by progenitor cell activity for myeloid lineages, but which lacks the potential to differentiate into lymphoid lineages. Methods are described by which the population is further subdivided into specific myeloid progenitor subsets, including common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitors (GMP). Methods are provided for the isolation and culture of these subpopulations, as are the properties of the myeloid lineages derived thereof. Claims of the invention include two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. Cell enrichment methods are provided, by which reagents that specifically recognize Thy-1; and IL-7R?a are employed in conjunction with other markers that are expressed on lineage-committed cells. Further described are the resulting myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, their growth and differentiation in vitro and in vivo. Therapeutic applications in transplantation are included. |
| Abstract: | A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7R.alpha., in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6761883 |
| Application Number: | US2001000956279 |
| Date Filed: | 17/09/2001 |
| Date Published: | 13/07/2004 |
| Assignee: | The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, USA |